Add Yahoo as a preferred source to see more of our stories on Google. Futuristic 3D cubes showing DNA base pairs and a double helix. (Getty Images) This story was originally published on BioPharma ...

Critical Path Institute’s® Critical Path for Alpha-1 Antitrypsin Deficiency Consortium today announced the addition of AIRNA as its newest industry partner, bringing RNA editing expertise to the ...

Beam Therapeutics (NASDAQ:BEAM) executives and clinical collaborators presented updated top-line data from the company’s ...

Shares of Vertex Pharmaceuticals (VRTX) were lower after the drugmaker said that it would not pursue VX-864, a drug to treat alpha 1 antitrypsin deficiency, into late-stage development. At last check ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recent studies attempted to improve the risk of recurrence while reducing the risk of adverse effect Alvelestat is an investigational oral neutrophil elastase inhibitor designed to protect AATD ...

Bernstein has upgraded Beam Therapeutics (NASDAQ:BEAM) to outperform from market perform, citing upcoming data on the company’s drug candidate for alpha-1 antitrypsin deficiency, or AATD. The ...

(RTTNews) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an inherited ...

CARLSBAD, Calif., Oct. 11, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with ...

Chronic obstructive pulmonary disease (COPD) remains highly prevalent among veterans, but the contribution of alpha-1 antitrypsin deficiency (AAT deficiency or AATD) to this patient population remains ...